Mivacron (Mivacurium Chloride)

Mivacurium chloride, the active ingredient in Mivacron, is a neuromuscular blocking agent presented as an injectable solution for intravenous use. It produces rapid skeletal muscle relaxation, facilitating endotracheal intubation and providing controlled muscle paralysis during a variety of surgical procedures.

GNH USA supplies Mivacron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product conforms to European Union quality standards and is distributed across global markets under strict regulatory oversight.

Mivacron, a neuromuscular blocking agent, is used to achieve temporary skeletal muscle relaxation in specific clinical settings.

- Endotracheal intubation: provides rapid muscle relaxation to facilitate tube placement. - Surgical procedures: maintains muscle paralysis for optimal operative conditions. - Brief diagnostic or therapeutic interventions: enables controlled muscle relaxation when short‑duration paralysis is required.

Mivacron may cause a range of adverse reactions after intravenous administration.

Common Side Effects: - Flushing: transient redness of the skin, often on the face or neck. - Hypotension: mild to moderate drop in blood pressure. - Tachycardia: increase in heart rate. - Bronchospasm: transient narrowing of the airways, especially in susceptible patients.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate intervention. - Prolonged apnea: extended respiratory paralysis beyond the expected duration. - Malignant hyperthermia: rare hypermetabolic crisis triggered by certain anesthetics. - Cardiac arrest: sudden loss of heart function. - Severe hypotension: marked drop in blood pressure leading to organ hypoperfusion. - Respiratory depression: significant reduction in breathing effort.

Before using Mivacron, clinicians should consider several safety measures.

- Assess patient history: verify absence of hypersensitivity to mivacurium or related neuromuscular blockers. - Monitor neuromuscular function: use peripheral nerve stimulators to gauge depth of blockade. - Evaluate plasma cholinesterase activity: patients with deficient enzymes may experience prolonged effects. - Adjust dosing in the elderly or those with hepatic/renal impairment: consider slower metabolism. - Maintain emergency airway equipment: be prepared for rapid re‑intubation if needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mivacron can interact with other agents that influence neuromuscular transmission or cardiovascular stability.

Major Interactions (Avoid): - Aminoglycoside antibiotics: may potentiate neuromuscular blockade. - Lithium: can enhance the paralytic effect. - Magnesium sulfate: increases susceptibility to blockade. - General anesthetics (e.g., propofol, volatile agents): additive depressant effect on respiration and muscle tone.

Moderate Interactions (Monitor Closely): - Volatile inhalational agents: may prolong duration of paralysis. - Beta‑adrenergic blockers: can affect hemodynamic response during blockade.